These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 8855175)

  • 1. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.
    Andreone P; Cursaro C; Gramenzi A; Zavagliz C; Rezakovic I; Altomare E; Severini R; Franzone JS; Albano O; Ideo G; Bernardi M; Gasbarrini G
    Hepatology; 1996 Oct; 24(4):774-7. PubMed ID: 8855175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.
    You J; Zhuang L; Cheng HY; Yan SM; Yu L; Huang JH; Tang BZ; Huang ML; Ma YL; Chongsuvivatwong V; Sriplung H; Geater A; Qiao YW; Wu RX
    World J Gastroenterol; 2006 Nov; 12(41):6715-21. PubMed ID: 17075991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, controlled, clinical study of thymosin alpha-1 versus interferon-alpha in [corrected] patients with chronic hepatitis B lacking HBeAg in China [corrected].
    You J; Zhuang L; Cheng HY; Yan SM; Qiao YW; Huang JH; Tang BZ; Ma YL; Wu GB; Qu JY; Wu RX
    J Chin Med Assoc; 2005 Feb; 68(2):65-72. PubMed ID: 15759817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B.
    Zavaglia C; Severini R; Tinelli C; Franzone JS; Airoldi A; Tempini S; Bettale G; Ideo G
    Dig Dis Sci; 2000 Apr; 45(4):690-6. PubMed ID: 10759236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
    Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.
    Yang YF; Zhao W; Zhong YD; Yang YJ; Shen L; Zhang N; Huang P
    Antiviral Res; 2008 Feb; 77(2):136-41. PubMed ID: 18078676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C.
    Sakai T; Shiraki K; Inoue H; Okano H; Deguchi M; Sugimoto K; Ohmori S; Murata K; Nakano T
    Int J Mol Med; 2002 Aug; 10(2):201-4. PubMed ID: 12119559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.
    Lampertico P; Del Ninno E; Manzin A; Donato MF; Rumi MG; Lunghi G; Morabito A; Clementi M; Colombo M
    Hepatology; 1997 Dec; 26(6):1621-5. PubMed ID: 9398007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
    Yuen MF; Hui CK; Cheng CC; Wu CH; Lai YP; Lai CL
    Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B.
    Lim SG; Wai CT; Lee YM; Dan YY; Sutedja DS; Wee A; Suresh S; Wu YJ; Machin D; Lim CC; Fock KM; Koay E; Bowden S; Locarnini S; Ishaque SM
    Antivir Ther; 2006; 11(2):245-53. PubMed ID: 16640105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial.
    Gregorio GV; Jara P; Hierro L; Diaz C; de la Vega A; Vegnente A; Iorio R; Bortolotti F; Crivellaro C; Zancan L; Daniels H; Portmann B; Mieli-Vergani G
    Hepatology; 1996 Apr; 23(4):700-7. PubMed ID: 8666320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B.
    Saruc M; Ozden N; Turkel N; Ayhan S; Hock LM; Tuzcuoglu I; Yuceyar H
    J Pharm Sci; 2003 Jul; 92(7):1386-95. PubMed ID: 12820143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of kurorinone versus interferon-alpha2a treatment in patients with chronic hepatitis B.
    Chen C; Guo SM; Liu B
    J Viral Hepat; 2000 May; 7(3):225-9. PubMed ID: 10849265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey.
    Saruc M; Yuceyar H; Kucukmetin N; Demir MA; Kandiloglu AR
    Hepatogastroenterology; 2002; 49(45):798-802. PubMed ID: 12063993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of chronic hepatitis B virus infection in childhood and efficacy of interferon therapy.
    Takano T; Tajiri H; Etani Y; Miyoshi Y; Tanaka Y; Brooks S
    Scand J Gastroenterol; 2015 Jul; 50(7):892-9. PubMed ID: 25861806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis.
    Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
    J Med Virol; 1997 Apr; 51(4):313-8. PubMed ID: 9093946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).
    Carreño V; Marcellin P; Hadziyannis S; Salmerón J; Diago M; Kitis GE; Vafiadis I; Schalm SW; Zahm F; Manzarbeitia F; Jiménez FJ; Quiroga JA
    Hepatology; 1999 Jul; 30(1):277-82. PubMed ID: 10385667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.